Effect of Pyridorin in Patients With Diabetic Nephropathy

Summary

The primary objective of the study is to evaluate the safety, tolerability and efficacy of Pyridorin (pyridoxamine dihydrochloride) up to 250 mg given orally twice daily in patients with diabetic kidney disease.

Timeline

Start

2002-07

Primary completion

—

Completion

2003-09

Drugs

Indications